See more : Mezzion Pharma Co.,Ltd. (140410.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of ACADIA Pharmaceuticals Inc. (ACAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ACADIA Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Keynote Financial Services Limited (KEYFINSERV.NS) Income Statement Analysis – Financial Results
- Gladstone Investment Corporation 4.875% Notes due 2028 (GAINZ) Income Statement Analysis – Financial Results
- Genovate Biotechnology Co., Ltd. (4130.TWO) Income Statement Analysis – Financial Results
- Hermès International Société en commandite par actions (HESAY) Income Statement Analysis – Financial Results
- Tata Investment Corporation Limited (TATAINVEST.BO) Income Statement Analysis – Financial Results
ACADIA Pharmaceuticals Inc. (ACAD)
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 726.44M | 517.24M | 484.15M | 441.76M | 339.08M | 223.81M | 124.90M | 17.33M | 61.00K | 120.00K | 1.15M | 4.91M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
| Cost of Revenue | 45.73M | 10.17M | 19.14M | 20.55M | 19.60M | 18.33M | 13.06M | 4.41M | 76.37M | 60.60M | 26.72M | 18.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 680.71M | 507.07M | 465.00M | 421.21M | 319.48M | 205.48M | 111.84M | 12.93M | -76.31M | -60.48M | -25.58M | -13.89M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
| Gross Profit Ratio | 93.70% | 98.03% | 96.05% | 95.35% | 94.22% | 91.81% | 89.54% | 74.58% | -125,095.08% | -50,401.67% | -2,233.80% | -283.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 351.62M | 361.58M | 239.42M | 319.13M | 240.39M | 187.16M | 149.19M | 99.28M | 73.87M | 60.60M | 26.72M | 18.79M | 17.31M | 20.58M | 41.59M | 56.75M | 57.94M | 49.40M | 30.85M | 23.45M | 16.94M | 14.92M | 13.09M | 9.73M |
| General & Administrative | 393.07M | 363.59M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
| Selling & Marketing | 9.40M | 5.50M | 41.80M | 51.10M | 38.30M | 39.80M | 15.60M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 402.47M | 369.09M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
| Other Expenses | 0.00 | 3.54M | 2.33M | -997.00K | 997.00K | -1.84M | 3.98M | 1.33M | 2.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.56M | 7.53M | 2.36M | 0.00 | 0.00 | 2.15M | 2.85M |
| Operating Expenses | 754.09M | 730.67M | 635.44M | 707.79M | 566.02M | 452.92M | 404.25M | 285.74M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
| Cost & Expenses | 799.82M | 740.83M | 654.58M | 728.34M | 585.62M | 471.25M | 417.31M | 290.15M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
| Interest Income | 17.23M | 6.61M | 591.00K | 6.61M | 11.17M | 5.35M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 82.00K | 409.00K | 2.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 86.00K | 181.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 2.03M | 3.34M | 2.93M | 2.77M | 3.01M | 2.71M | 1.83M | 647.00K | 206.00K | 79.00K | 109.00K | 285.00K | 607.00K | 1.11M | 1.04M | 768.00K | -146.00K | 1.03M | 1.31M | 1.34M | 1.40M | 0.00 | 0.00 |
| EBITDA | -67.83M | -221.57M | -167.10M | -286.59M | -243.78M | -244.44M | -289.70M | -270.99M | -163.47M | -93.02M | -38.22M | -20.78M | -22.48M | 15.70M | -44.36M | -66.98M | -62.65M | -49.05M | -32.93M | -24.18M | -12.40M | -11.22M | -15.28M | -11.27M |
| EBITDA Ratio | -9.34% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,337.82% | -425.64% | -1,091.78% | 37.26% | -693.19% | -4,212.45% | -819.14% | -646.92% | -317.45% | -538.40% | -168.01% | -178.84% | -411.39% | -261.34% |
| Operating Income | -73.38M | -223.60M | -170.44M | -286.59M | -246.55M | -247.44M | -292.41M | -272.82M | -164.61M | -93.23M | -38.30M | -20.89M | -22.85M | 15.09M | -45.47M | -66.98M | -62.65M | -49.05M | -35.81M | -26.10M | -13.74M | -12.63M | -15.28M | -11.27M |
| Operating Income Ratio | -10.10% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,344.72% | -425.64% | -1,105.56% | 35.82% | -710.55% | -4,212.45% | -829.31% | -603.15% | -326.81% | -566.76% | -186.22% | -201.19% | -411.39% | -261.34% |
| Total Other Income/Expenses | 22.34M | 10.15M | 2.92M | 5.61M | 12.16M | 3.51M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 45.00K | 323.00K | 2.73M | 6.26M | 3.96M | -4.55M | 178.20K | 0.00 | 0.00 | 15.28M | 11.27M |
| Income Before Tax | -51.04M | -213.44M | -167.52M | -280.97M | -234.38M | -243.94M | -288.28M | -270.05M | -164.11M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -7.03% | -41.27% | -34.60% | -63.60% | -69.12% | -108.99% | -230.81% | -1,558.20% | -269,037.70% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 10.25M | 2.53M | 351.00K | 611.00K | 876.00K | 1.26M | 1.12M | 1.34M | 330.00K | -206.00K | 0.00 | -109.00K | 0.00 | 0.00 | 0.00 | -1.04M | 0.00 | -3.86M | -200.00 | -200.00 | 352.60K | 242.30K | 14.41M | 10.19M |
| Net Income | -61.29M | -215.98M | -167.87M | -281.58M | -235.26M | -245.19M | -289.40M | -271.39M | -164.44M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | -14.09M | -12.87M | -14.41M | -10.19M |
| Net Income Ratio | -8.44% | -41.76% | -34.67% | -63.74% | -69.38% | -109.56% | -231.71% | -1,565.94% | -269,578.69% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | -191.00% | -205.05% | -387.88% | -236.41% |
| EPS | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -9.66 | -8.86 | -11.93 | -9.53 |
| EPS Diluted | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -1.24 | -8.86 | -11.93 | -9.53 |
| Weighted Avg Shares Out | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 54.87M | 52.18M | 38.59M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 1.46M | 1.45M | 1.21M | 1.07M |
| Weighted Avg Shares Out (Dil) | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 55.12M | 52.18M | 38.72M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 11.37M | 1.45M | 1.21M | 1.07M |
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 18, 2024 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations...
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for...
3 Pharma Stocks to Sell in March Before They Crash & Burn
Recent trends in the stock market have seen a shift in investor interest from tech giants, known as the Magnificent 7, towards pharmaceutical companies, particularly those involved in weight-loss drugs. But, it's important to identify which pharma stocks to sell...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for...
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia's...
Evaluating Acadia's Market Position Following Pimavanserin's Clinical Setback
Acadia's new drug, Daybue, shows promising initial sales, but pimavanserin failed in schizophrenia trials, impacting stock value. Nuplazid's patent protection may shield it from generic competition until at least 2030, with steady sales growth reported. Daybue faces challenges with patient...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for...
Source: https://incomestatements.info
Category: Stock Reports